IngredientsSystematic chemical name: Glycitein is scientifically designated as 7,4′-dihydroxy-6-methoxyisoflavone, an important isoflavone molecule initially extracted from soybean germ. It is also frequently rendered in older literature as glycetein, a spelling variant of the same compound. The IUPAC name reflects the compound's structural hallmark: the presence of a methoxy (–OCH₃) substituent at position 6 of the isoflavone A-ring, combined with hydroxyl groups at the 7 and 4′ positions.
Class and molecular weight: Glycitein (4′,7-dihydroxy-6-methoxyisoflavone) accounts for 5–10% of the total isoflavones in soy food products. Its molecular weight is 284.3 g/mol. The CAS registry number is 40957-83-3.
Classification as a phytoestrogen: Glycitein is an O-methylated isoflavone which accounts for 5–10% of the total isoflavones in soy food products. Glycitein is a phytoestrogen with weak estrogenic activity, comparable to that of the other soy isoflavones.
Relationship to its glycoside form: The three isoflavones in soybeans are the β-glucosides genistin, daidzin, and glycitin, and their respective aglycones, genistein, daidzein, and glycitein. When glycitein is bound to a glucose molecule, the resulting compound is called glycitin; glycitein itself is the free aglycone. Like other isoflavonoids, glycitein is synthesized as a glycoside conjugate to a monosaccharide (typically glucose). The glycoside is hydrolyzed during digestion to the biologically active free isoflavonoid.
Biosynthesis: Glycitein is synthesized from phenylalanine, similarly to other isoflavonoids. The biosynthesis involves 8 steps, resulting in free glycitein; a subsequent glucosyltransferase-catalyzed reaction results in the corresponding glucoside, glycitin. At the genetic level, gene structure analysis has indicated that the flavonoid 6-hydroxylase gene (F6H4) is required for glycitein synthesis; in soybean lines with insertional mutations in this gene, the accumulation of glycitein isoflavones is absent. A second gene, IOMT3 (isoflavone O-methyltransferase), is also required: a premature stop codon in this gene results in the accumulation of 6-hydroxydaidzein precursors rather than glycitein.
Primary botanical source: The soybean, Glycine max (L.) Merrill (family Fabaceae/Leguminosae), is the predominant natural source of glycitein. Soybean (Glycine max) isoflavones are among the most important secondary metabolites, with functional benefits for human health. Soybeans accumulate three aglycone forms of isoflavones: genistein, daidzein, and glycitein.
Proportion within soy isoflavones: The three isoflavones in soybeans—genistein, daidzein, and glycitein—and their respective glycosides (the predominant form in soybeans and unfermented soy foods) account for approximately 50, 40, and 10%, respectively, of the total soybean isoflavone content. This makes glycitein the least abundant of the three principal soy isoflavones. Soy contains variable amounts of genistein and daidzein as the major isoflavones (approximately 47 and 44%, respectively) and minor amounts of glycitein (approximately 9% of the total isoflavones in soybeans).
Concentration in soy germ: Glycitein and its glycoside glycitin are notably more concentrated in the soybean hypocotyl (germ) than in the whole bean or other soy fractions. Supplements that contained high levels of glycitin and glycitein were apparently manufactured from extracts of the soy germ, as this is a major isoflavone of the soybean hypocotyl.
Conjugate forms in the plant: In the soybean before processing, the glucosylated isoflavones are esterified with malonic acid at the 6-hydroxyl position of the glucose moiety. This is important because processing to make soy foods may or may not retain the ester group. Accordingly, glycitein occurs in four molecular forms within the soy matrix: the free aglycone glycitein, the β-glucoside glycitin, and the malonyl- and acetyl-glycoside derivatives. For soy foods made from defatted soy flour and then toasted, the malonyl group is decarboxylated to an acetyl group—a change that may also apply to isolated soy protein. In fermented soy foods, the glucosyl groups are removed and modification of the isoflavone may have occurred.
Effect of fermentation: In fermented soy foods, such as miso, tempeh, and natto, to varying degrees isoflavones are present as aglycones. The degree to which the glycosides are converted to aglycones depends upon the bacteria used and the duration of fermentation.
Effect of germination on content: The bioavailability of total daidzein, glycitein, and genistein increased during soybean germination, reaching 143 ± 30%, 184 ± 32%, and 130 ± 24%, respectively. This suggests that sprouted or germinated soybean preparations may deliver significantly higher amounts of the bioavailable aglycone relative to ungerminated beans.
Varietal and environmental influences: The chemical composition, including the isoflavone content, of different soy-food preparations is variable and dependent on soybean strain, growing conditions, harvest time, and processing method.
Glycitein is available as a constituent of a variety of commercial preparations, primarily within the broader category of soy isoflavone supplements:
Glycitein itself has never been the subject of targeted traditional use as an isolated compound; it exists in the context of whole soy foods whose consumption has a multi-millennia history primarily in East Asian cultures. The ethnobotanical and food-history record concerns soy as a whole food rather than its individual isoflavone constituents.
East Asian dietary context: Soybeans have been cultivated and consumed in China for at least three thousand years, spreading subsequently to Japan, Korea, and Southeast Asia. Traditional preparations including tofu, miso, natto, tempeh, and soy milk provided varying amounts of soy isoflavones—including glycitein—to populations in these regions on a daily basis. Soy, a major component of the diet for centuries, contains the largest concentration of isoflavones, a class of phytoestrogens.
Traditional medicine uses of soy: In traditional Chinese medicine, preparations from the soybean (Dou) and its sprout (Da Dou Juan, corresponding to Sojae Semen Germinatum) have historically been used for conditions including febrile illness, restlessness, and general tonic effects. Sojae Semen Germinatum is a processed soybean product germinated using mature seeds of Glycine max (L.) Merr., with therapeutic benefits for osteoporosis acknowledged in more recent ethnopharmacological literature. The specific isoflavone profile of germinated soy, which is enriched in free aglycones including glycitein, has attracted modern scientific interest as a mechanistic basis for these traditional uses.
The characterization of glycitein as an individual chemical entity and the investigation of its specific biological properties is an entirely modern scientific endeavour, with the earliest dedicated studies appearing in peer-reviewed literature from the late 1990s onward. Glycitein accounts for 5–10% of the total isoflavones in soy food products; the biological activity of this compound had not been reported until 1999, although numerous studies had been performed with the other soy isoflavones, daidzein and genistein.
The term "glycitein" refers specifically to a single molecular entity, 7,4′-dihydroxy-6-methoxyisoflavone. Its structural distinctiveness among the three soy isoflavones lies in the methoxy group at position 6 of the A-ring, which is absent from both genistein and daidzein. This structural feature may influence its receptor binding profile, metabolic stability, and specific biological activities compared to the other soy isoflavones.
Structural basis of antioxidant activity: Structural studies indicate that the antioxidant effects of glycitein are chiefly due to the phenolic hydroxyl groups in its molecular structure.
Broader soy isoflavone chemical context: The principal isoflavones and most researched soy constituents are genistein (4′,5,7-trihydroxyisoflavone) and daidzein (4′,7-dihydroxyisoflavone). Glycitein is another isoflavone found in soy, but relatively little is published on its biological activity. In addition to isoflavones, soybeans contain lignans, coumestans, saponins, plant sterols, phytates, and protease inhibitors. When glycitein is consumed as part of whole soy foods or mixed isoflavone supplements, it acts alongside these other constituents, and attributing specific effects to glycitein alone—rather than to the total isoflavone mixture—is methodologically challenging.
Isoflavones have a similar chemical structure to estrogen, bind to estrogen receptors (ERs), and exert estrogen-like effects under certain experimental conditions. For this reason, they are commonly classified as phytoestrogens.
DES, 17β-estradiol, and three isoflavones (daidzein, genistein, and glycitein) have been examined for their competitive binding abilities with 17β-[³H]estradiol to estrogen receptor proteins of mouse uterine cytosol. In an animal study, uterine weight increased 150% with glycitein (p < 0.001), 50% with genistein (p < 0.001), and 60% with DES (p < 0.001) compared with the control group—a standard in-vivo uterotrophic assay endpoint indicating estrogenic activity in immature rodents. This result demonstrates estrogenic potency in the mouse model, though its direct relevance to human estrogenic signaling requires cautious interpretation.
Glycitein has been characterised as a selective estrogen receptor modulator (SERM): glycitein is a Selective Estradiol Receptor Modulator (SERM) from soy. Estrogen receptors ER-α and ER-β mediate estrogen effects; ER-α is mainly distributed in tissues such as the breast and uterus, while ER-β is commonly found in the central nervous system, bones, ovaries, adrenal glands, and urinary system. Research has shown that glycitin was an efficient selective estrogen receptor modulator (SERM) that exhibited agonistic or antagonistic effects when bound to receptors on the bone.
Glycitein demonstrates diverse antioxidant capabilities mainly by regulating the nuclear factor erythroid 2-related factor 2–antioxidant response element (Nrf2-ARE) signaling pathway. At the molecular level, it increases cellular antioxidant capacity and mitigates oxidative stress-induced damage by modulating critical signaling pathways, including Nrf2-mediated antioxidant responses and NF-κB-driven inflammatory cascades.
In a model organism study, the antioxidant activity of glycitein correlated with a reduced level of hydrogen peroxide in transgenic C. elegans. In vitro scavenging effects of glycitein on three types of reactive oxygen species confirmed its antioxidant properties.
Mechanistically, accompanying reactive oxygen species (ROS), glycitein can activate mitogen-activated protein kinase (MAPK) and inhibit the signal transducer and activator of transcription 3 (STAT3) and nuclear factor-kappaB (NF-κB) signaling pathways.
Glycitein markedly decreased mitochondrial transmembrane potential (ΔΨm) and increased mitochondrial-related apoptosis in cancer cells, and caused G0/G1 cell cycle arrest by regulating cycle-related proteins. Mechanistically, glycitein can activate MAPK and inhibit STAT3 and NF-κB signaling pathways.
Research has shown that glycitein inhibited matrix metalloproteinase-1 (MMP-1) and increased collagen by downregulating extracellular regulated JNK, protein kinases (ERK), and p38 mitogen-activated protein kinase (MAPK). In fibroblast studies, treatment with glycitin included elevated synthesis of collagen types I and III, increased levels of fibronectin and TGF-β, enhanced phosphorylation of Smad2, Smad3, and AKT, and decreased levels of MMP-1.
Glycitin activated the gene expression of collagen type I (Col I) and alkaline phosphatase (ALP) in bone marrow stem cells (BMSCs). Notably, glycitin suppressed protein expression of TGF-β and AKT in BMSCs. These results indicated that glycitin may regulate osteoblasts through TGF-β or AKT signaling pathways in BMSCs.
Glycitein activates extracellular signal-regulated kinase via vascular endothelial growth factor receptor signaling in nontumorigenic (RWPE-1) prostate epithelial cells, according to a study published in the Journal of Nutritional Biochemistry (Clubbs and Bomser, 2007). This mechanism is distinct from those observed with genistein in the same cell line.
It is critical to note at the outset that the overwhelming majority of research specifically examining glycitein—as opposed to mixed soy isoflavones—consists of in vitro cell studies and animal models. The principal isoflavones and most researched soy constituents in soy are genistein and daidzein; glycitein is another isoflavone found in soy, but relatively little is published on its biological activity. Human clinical evidence for glycitein as an isolated compound is essentially absent; wherever clinical studies exist, they involve mixed soy isoflavone preparations in which glycitein is a minor constituent.
Gastric cancer (in vitro): A study evaluated the antitumor effects of glycitein on human gastric cancer cells and investigated the underlying mechanisms using MTT assay, flow cytometry, and western blotting. The results showed that glycitein had significant cytotoxic effects on human gastric cancer cells. These findings suggested that glycitein induced cell apoptosis and G0/G1 phase cell cycle arrest via ROS-related MAPK/STAT3/NF-κB signaling pathways; the authors suggested glycitein has the potential to be a novel targeted therapeutic agent for human gastric cancer. This evidence is preclinical only (cell culture); no human clinical data exist to support a clinical use claim.
Breast and prostate cancer (in vitro): Glycitein is an isoflavone that reportedly inhibits the proliferation of human breast cancer and prostate cancer cells. These findings are likewise from cell culture studies and have not been replicated in controlled human trials.
Strength of evidence: All current anti-cancer evidence for glycitein is preclinical (in vitro). No clinical trials have examined glycitein alone for cancer prevention or treatment.
Osteoblast cell studies: Administration of glycitin increased cell proliferation and promoted osteoblast formation from BMSCs. Furthermore, glycitin activated the gene expression of Col I and ALP in BMSCs. Notably, glycitin suppressed protein expression of TGF-β and AKT in BMSCs. These results indicated that glycitin may regulate osteoblasts through TGF-β or AKT signaling pathways in BMSCs.
Anti-osteoporosis animal evidence: Research has shown that isolated glycitin from fermented black soybean had strong anti-osteoporosis activity in relevant animal or cell models. Additionally, the health effects attributed to glycitin include estrogenic effects and anti-osteoporosis effects, as well as antioxidant, anti-tumor, hypolipidemic, and hypoglycemic effects.
Clinical context: Clinical evidence for bone health benefits derives from studies on mixed soy isoflavone preparations, not glycitein specifically. Some randomized trials—particularly those using genistein-rich standardized doses over 12–24 months—show maintenance or small gains in bone mineral density at specific sites. Many clinical trials used mixed isoflavone extracts standardized to genistein, daidzein, and glycitein, with most benefits correlating with the total isoflavone dose. Direct attribution of bone effects to glycitein specifically is not currently supported by clinical data.
Strength of evidence: Preclinical (cell, animal). The contribution of glycitein to bone outcomes observed in mixed isoflavone clinical trials cannot be isolated.
Model organism (C. elegans) study: Transgenic C. elegans, that express human beta amyloid (Aβ), were fed with soy-derived isoflavones genistein, daidzein, and glycitein (100 μg/mL) and then examined for Aβ-induced paralysis and the levels of reactive oxygen species. Among the three compounds tested, only glycitein alleviated Aβ expression-induced paralysis in the transgenic C. elegans. This activity correlated with a reduced level of hydrogen peroxide. The transgenic C. elegans fed with glycitein exhibited reduced formation of beta amyloid. These findings suggest that a specific soy isoflavone glycitein may suppress Aβ toxicity through combined antioxidative activity and inhibition of Aβ deposition, thus may have therapeutic potential for prevention of Aβ-associated neurodegenerative disorders.
Strength of evidence: This finding is exclusively from an invertebrate model organism. No mammalian or human clinical evidence for neuroprotective effects of glycitein exists.
Smooth muscle cell studies: A study cited in the scientific literature (Pan et al., Journal of Nutrition, 2001, PMID referenced under MedChemExpress citation index 11-29–11-31) found that genistein, daidzein, and glycitein inhibit growth and DNA synthesis of aortic smooth muscle cells from stroke-prone spontaneously hypertensive rats. This was an in vitro/ex vivo animal study.
Strength of evidence: Preclinical only. No human clinical trials have examined glycitein's cardiovascular effects as an isolated agent.
Fibroblast studies: Among other biological effects, glycitein demonstrates antioxidant effects. Dermal fibroblasts treated with glycitein showed an increased cell proliferation and migration, increased synthesis of collagen types I and III, and decreased MMP-1.
Photoprotection: Results in this area are mixed. Huang et al. investigated the photoprotective activity of soy aglycones and found that UVB-induced H₂O₂ levels in the HaCaT cell line were significantly reduced in the presence of genistein and daidzein (with daidzein being more effective), while no activity was observed for glycitein. This contrasts with other in vitro observations on glycitein's antioxidant capacity and suggests the compound's photoprotective activity in skin keratinocytes may be limited compared to the other soy isoflavones.
Clinical context: A growing body of research indicates that soy supplementation contributes to both skin health and appearance through a variety of mechanisms, favorably influencing various dermatologic parameters such as hydration, elasticity, collagen synthesis, skin barrier function, fine lines, and wrinkles. The three isoflavones in soybeans—genistein, daidzein, and glycitein—by binding to estrogen receptors (ERα and ERβ), may exert some of the same effects as estrogen, although they may also exert effects opposite to those of estrogen. However, clinical studies in this area use mixed soy isoflavone preparations; no clinical trials have isolated glycitein's dermatological contribution.
Strength of evidence: In vitro only; mixed signals across cell types. No clinical data for isolated glycitein.
As described under mechanisms of action, glycitein binds estrogen receptors and exerts SERM-like activity in preclinical models. The uterotrophic response observed in immature rodents (150% increase in uterine weight with glycitein at 3 mg/day for 4 days, p < 0.001) is used as a standard measure of estrogenic potency in vivo. However, the estrogenic activity of glycitein in the human context has not been studied independently. All human trials addressing menopausal symptom relief from soy isoflavones concern mixed preparations predominantly standardised to genistein.
The health effects attributed to glycitin include hypolipidemic and hypoglycemic effects, according to a 2025 review in Foods (MDPI). These effects have been characterised in cell and animal models, but no human clinical data for isolated glycitein exists in this area.
A 2025 study in the Journal of Agricultural and Food Chemistry examined glycitein's effect on soybean allergen structure. The potential of glycitein, a dietary isoflavone, to modulate soybean β-conglycinin (7S) allergenicity was evaluated. Glycitein bound to 7S mainly through hydrogen bonding and van der Waals forces, loosening its conformation to enhance protease accessibility and digestibility. In vitro, glycitein moderately reduced IgE binding and significantly decreased β-hexosaminidase and IL-6 release. In vivo, allergic reactions were weakened, with lower antibody levels in serum and significant suppression of IL-4 in spleen. Glycitein also partially restored Th1/Th2 balance and modulated gut microbiota composition. These are animal and in vitro findings; no clinical studies have been conducted.
Absorption characteristics: Glycitein is one of the best-absorbed flavonoids. Plasma steady-state level can be achieved by several intakes a day. Glycitein bioavailability is similar to that of daidzein and its urinary excretion is significantly higher than that of genistein. Equol does not affect glycitein bioavailability.
Human pharmacokinetic study: A study reported plasma bioavailability and urine excretion of glycitein compared to other soy isoflavones after a unique intake of a food supplement based on soy germ containing 55.24 mg isoflavones. Eighteen plasma and urinary sampling profiles collected over 48 hours from healthy young Caucasian men were analysed using specific ELISAs. Glycitein T(max), C(max), AUC(0→24h) and T(½) in plasma were calculated.
Pharmacokinetics of the glycoside form (glycitin): Glycitin, found in phytoestrogen supplements, underwent hydrolysis of the β-glycoside moiety and little further biotransformation, leading to high plasma glycitein concentrations. This distinguishes glycitein's metabolic fate from that of formononetin or biochanin A (found in red clover supplements), which undergo more extensive demethylation.
Methoxylated isoflavone pharmacokinetics: The pharmacokinetics of methoxylated isoflavones show distinct differences depending on the position of the methoxyl group in the molecule.
Urinary excretion: Various studies reported data on glycitein urine excretion, with excretion rates from 20% to 55% over periods varying from 40 to 48 hours using liquid chromatography analytical methods.
Food matrix effects: The factors influencing isoflavone bioavailability vary depending on absorption and metabolism of the isoflavones, which in turn depend on the specific chemical forms of the isoflavones and the intestinal environment. The relative bioavailability of soymilk is lower than that of fermented soybeans because the aglycone ratio in soymilk is lower; bioavailability increases as the percentage of aglycones increases.
Gender differences: Metabolism of glycitein from soy food was found to be slightly different between women and men. The human pharmacokinetic study described above was conducted in men specifically to avoid confounding from hormonal fluctuations.
Based on the available preclinical literature, glycitein has been studied in relation to the following body systems and health domains. The evidence in all areas is currently preclinical unless otherwise specified:
The following doses appear specifically in the cited scientific literature and are reported descriptively only:
No established human therapeutic dosage for glycitein as an isolated compound has been published in the reviewed clinical literature. Doses used in human studies are invariably expressed as total isoflavone content of mixed preparations.
Glycitein is a phytoestrogen with weak estrogenic activity, comparable to that of the other soy isoflavones. The SERM-like nature of glycitein—agonistic at some receptor subtypes or tissues and potentially antagonistic at others—means that its net effect in hormone-sensitive tissues is not straightforwardly predictable from its receptor binding data alone. The relevance of the pronounced uterotrophic response in immature rodents (uterine weight increased 150% with glycitein at p < 0.001 in mouse models) to adult human physiology requires careful contextualisation, as immature rodent uterotrophic assays are known to overestimate estrogenic potency relative to human responses at dietary exposure levels.
Glycitein is a constituent of soybean and soy-derived products. Individuals with soy allergy should be aware that soy germ extracts, the richest source of glycitein/glycitin supplements, derive directly from the allergenic soy matrix.
Estradiol binds to Sex Hormone Binding Globulin (SHBG) in plasma, as do, to some extent, the soy isoflavones. Fluctuations in estradiol levels in plasma may impact isoflavone bioavailability. This interaction could theoretically affect the pharmacokinetics of glycitein in individuals with altered SHBG levels (e.g., due to liver disease, thyroid dysfunction, or concurrent hormonal medications), though this has not been investigated specifically for glycitein.
Soy isoflavones as a class have been studied for potential interactions with thyroid hormone synthesis and thyroid medication absorption; however, the existing evidence pertains to the soy isoflavone mixture (primarily genistein and daidzein) rather than to glycitein in isolation. No studies specifically addressing glycitein's effects on thyroid function have been identified in the reviewed literature.
The safety profile of glycitein as an isolated compound at supplemental doses has not been characterised in human clinical trials. Safety assessments documented in the literature relate to mixed soy isoflavone preparations. The absence of dedicated human safety data for isolated glycitein means that definitive statements about its tolerability, side-effect profile, or drug interaction potential in humans cannot be made based on current evidence.
Glycitein is the least-studied of the three principal soy isoflavones. Glycitin is a kind of compound found in soybeans that has attracted increasing attention as a good source of nutrients due to its potential applications in medicine, cosmetics, and food. A 2025 comprehensive review in Foods (MDPI) summarised the state of knowledge: the present review summarises recent progress made on the structures and functions of glycitin, with future perspectives to maximise their value and applications. The health effects attributed to glycitin include estrogenic effects and anti-osteoporosis effects, as well as antioxidant, anti-tumor, hypolipidemic, and hypoglycemic effects.
Notwithstanding this growing interest, the totality of human clinical evidence specific to glycitein remains absent. All mechanistic and efficacy data are derived from in vitro cell studies, animal models, and invertebrate model organisms. Clinical trials that have included glycitein have done so as a minor component of mixed soy isoflavone preparations, making it impossible to attribute clinical outcomes to glycitein specifically. Future research distinguishing glycitein's individual contributions from those of genistein and daidzein in both efficacy and safety contexts is a recognised gap in the scientific literature.
Health conditions that Glycetein may help support.
Body systems that Glycetein may help support.
Go back